

PHARMACOKINETICS

ChemPartner's pharmacokinetics team of over 200 scientists knows that preclinical pharmacokinetics research is a vital part of drug development pipelines as it informs dosing regimens, toxicology studies, formulation development, and more. Our AAALAC and OLAW accredited animal facilities offer our clients access to broad ranges of animal species as well as state-of-the-art instruments.

EXPERTISE

ChemPartner conducts 120-150 PK studies per week and our extensive experience includes PK model development with comprehensive *in vivo* techniques such as surgical operation and animal care.

EXPERIENCE AND CAPABILITIES

- Founded in 2007
- 200+ scientists, 50% with MS/MD/PhD
- 10,000+ PK/PD/tox case studies and 100,000+ ADME case studies
- Quality Data
 - Well established process and QC system to ensure data quality
- Fast Turnaround Time
 - 5 working days from compound receipt to data delivery for most small molecule PK
- Flexibility
 - Last minute change allowed to accommodate R&D need
- Extensive Experience
 - Over 10,000 PK studies and 150 clients globally

COMPREHENSIVE IN VIVO TECHNIQUES

- Cannulation surgery including jugular vein, portal vein, duodenum, and bile duct
- Dosing routes include: IV, PO, SC, IM, nasal, ICV, and AZ pump
- Tissue collection including spinal cord, sciatic nerve, specific brain regions, cornea, others upon request

FORMULATION SUPPORT

- Formulation Screening
 - Pharmacology
 - Pharmacokinetics
 - Toxicology
- Solubility test in formulation under pH 3-9
- Stability test for dosing solution

Rat

- SD

Gerbil

Ferret

– Wister

- Wister Han

• Dilution study to predict *in vivo* precipitation and supersaturation

ANIMALS AND FACLITIES

AAALAC ACCREDITED ANIMAL VIVARIUM

- 40,000 ft² special pathogen free (SPF) rodent facility
- 18,000 ft² large animal facility
- Advanced animal care program
- Animal enrichment program

SMALL ANIMALS

- Mouse

 C57BL/6
 - CD-1
 - Balb/c nude
- Guinea pig
- Rabbit

LARGE ANIMALS

- Mini-pig
- Canine
 - Beagle
- Non-human primates
 Cynomolgus monkey
 - Rhesus monkey

EXTENSIVE PK MODELS





ANTIBODY-DRUG CONJUGATES



PK AND PD CORRELATION





- PO administration of CpdN at 5 mg/kg to SD rats for two consecutive days
- Plasma levels of biomarker A and B correlate with drug concentration change

Total antibody and ADC quantified by ELISA

- Free drug analyzed by LC-MS/MS
- Free drug concentration at LLOQ (0.1 ng/ mL) in systemic circulation

PK PARAMETERS	UNIT	TOTAL Ab	ADC
CL	mL/day/kg	8.23	14.7
Vss	ml/kg	102	103
VI	ml/kg	44.3	50.6
Alpha t1/2	day	0.309	0.204
Beta t1/2	day	9.38	5.18